About Morning

Sources

The labels, trials and guidance behind every Morning guide.

Every figure in Morning’s guides comes from a source listed here: FDA prescribing information, peer-reviewed trials and public health guidance. Each guide lists its own sources at the end; this page gathers them all.

How we choose and check them: Editorial policy.

GLP‑1 side effects, week by week6 sourcesRead the guide →
Nausea on a GLP‑1: why it happens and what helps9 sourcesRead the guide →
Constipation on a GLP‑1: causes, fixes, red flags9 sourcesRead the guide →
Diarrhea on GLP‑1s: how long it lasts and what helps9 sourcesRead the guide →
Sulfur burps, heartburn and reflux on GLP‑1s8 sourcesRead the guide →
Fatigue on a GLP‑1, and what helps6 sourcesRead the guide →
Hair loss on a GLP‑1: why it happens and what helps7 sources
  • WEGOVY (semaglutide) injection and tablets, prescribing information, revised 6/2026. DailyMed
  • ZEPBOUND (tirzepatide) injection, prescribing information, revised 8/2026. uspl.lilly.com
  • American Academy of Dermatology. Do you have hair shedding or hair loss? aad.org
  • American Academy of Dermatology. Hair loss: 18 causes. aad.org
  • US Food and Drug Administration. Biotin interference with troponin lab tests. fda.gov
  • DermNet. Telogen effluvium. dermnetnz.org
  • US Departments of Agriculture and Health and Human Services. Dietary Guidelines for Americans, 2025–2030. cdn.realfood.gov/DGA.pdf
Read the guide →
Ozempic face: what it is and what actually helps9 sources
  • Sharma RK, et al. Radiographic midfacial volume changes in patients on GLP-1 agonists. Otolaryngology–Head and Neck Surgery, 2025;173(2):360–366. doi.org/10.1002/ohn.1209
  • Humphrey CD, Lawrence AC. Implications of Ozempic and other semaglutide medications for facial plastic surgeons. Facial Plastic Surgery, 2023;39(6):719–721. doi.org/10.1055/a-2148-6321
  • Lee KWA, et al. Ozempic face: an update and critical review. Journal of Cosmetic and Regenerative Medicine, 2026;1(1):19. doi.org/10.65381/jcrm.2026.01010019
  • Alam M, et al. Association of facial exercise with the appearance of aging. JAMA Dermatology, 2018;154(3):365–367. doi.org/10.1001/jamadermatol.2017.5142
  • WEGOVY (semaglutide) injection and tablets, prescribing information, revised 6/2026. DailyMed
  • ZEPBOUND (tirzepatide) injection, prescribing information, revised 8/2026. uspl.lilly.com
  • American Academy of Dermatology. 11 ways to reduce premature skin aging. aad.org
  • US Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd edition. odphp.health.gov
  • US Departments of Agriculture and Health and Human Services. Dietary Guidelines for Americans, 2025–2030. cdn.realfood.gov/DGA.pdf
Read the guide →
Zepbound and Mounjaro side effects5 sourcesRead the guide →
Wegovy and Ozempic side effects, explained4 sourcesRead the guide →
How GLP‑1 medications work, in plain words11 sourcesRead the guide →
Your first month on a GLP‑1, week by week4 sources
  • Wegovy (semaglutide) injection and tablets, prescribing information, Medication Guide and Instructions for Use. Novo Nordisk. DailyMed
  • Ozempic (semaglutide) injection, prescribing information, Medication Guide and Instructions for Use. Novo Nordisk. DailyMed
  • Zepbound (tirzepatide) injection, prescribing information, Medication Guide and Instructions for Use. Eli Lilly. DailyMed
  • Mounjaro (tirzepatide) injection, prescribing information, Medication Guide and Instructions for Use. Eli Lilly. DailyMed
Read the guide →
GLP‑1 shot day: what to expect and what to eat4 sources
  • Wegovy (semaglutide) injection and tablets, prescribing information, Medication Guide and Instructions for Use. Novo Nordisk. DailyMed
  • Ozempic (semaglutide) injection, prescribing information, Medication Guide and Instructions for Use. Novo Nordisk. DailyMed
  • Zepbound (tirzepatide) injection, prescribing information, Medication Guide and Instructions for Use. Eli Lilly. DailyMed
  • Mounjaro (tirzepatide) injection, prescribing information, Medication Guide and Instructions for Use. Eli Lilly. DailyMed
Read the guide →
GLP‑1 injection sites and how to rotate them4 sources
  • Wegovy (semaglutide) injection, prescribing information, Medication Guide and Instructions for Use (pen, prefilled syringe and FlexTouch). Novo Nordisk. DailyMed
  • Ozempic (semaglutide) injection, prescribing information, Medication Guide and Instructions for Use (pens and prefilled syringe). Novo Nordisk. DailyMed
  • Zepbound (tirzepatide) injection, prescribing information, Medication Guide and Instructions for Use (single-dose pen, vials and KwikPen). Eli Lilly. DailyMed
  • Mounjaro (tirzepatide) injection, prescribing information, Medication Guide and Instructions for Use (single-dose pen, vials and KwikPen). Eli Lilly. DailyMed
Read the guide →
Weight-loss plateaus on a GLP‑112 sources
  • Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 2022;28:2083–2091. doi.org/10.1038/s41591-022-02026-4
  • Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021;384:989–1002. doi.org/10.1056/NEJMoa2032183
  • Tools for Practice #295. Summary of STEP 1, noting weight loss plateaued around week 60. College of Family Physicians of Canada, 2021. cfpclearn.ca
  • Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022;387:205–216. doi.org/10.1056/NEJMoa2206038
  • Horn DB, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clinical Obesity, 2025;15(3):e12734. doi.org/10.1111/cob.12734
  • Ard J, et al. Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1. Diabetes, Obesity and Metabolism, 2025;27(9):5064–5071. doi.org/10.1111/dom.16554
  • Orsama AL, et al. Weight rhythms: weight increases during weekends and decreases during weekdays. Obesity Facts, 2014;7(1):36–47. doi.org/10.1159/000356147
  • Polidori D, et al. How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake. Obesity, 2016. doi.org/10.1002/oby.21653
  • Nedeltcheva AV, et al. Insufficient sleep undermines dietary efforts to reduce adiposity. Annals of Internal Medicine, 2010. pubmed.ncbi.nlm.nih.gov/20921542
  • US Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd edition. health.gov
  • Wegovy (semaglutide) prescribing information, FDA. DailyMed
  • Zepbound (tirzepatide) prescribing information, FDA. DailyMed
Read the guide →
Semaglutide vs tirzepatide, side by side8 sourcesRead the guide →
Wegovy vs Ozempic, Zepbound vs Mounjaro5 sourcesRead the guide →
The Wegovy pill, explained4 sourcesRead the guide →
Traveling with a GLP‑1 pen: storage, TSA and shot day12 sourcesRead the guide →
Coming off a GLP‑1: how to keep the weight off5 sources
  • Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. doi.org/10.1111/dom.14725
  • Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA, 2024;331(1):38-48. jamanetwork.com
  • Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021. doi.org/10.1056/NEJMoa2032183
  • Wegovy (semaglutide) prescribing information, FDA. DailyMed
  • Zepbound (tirzepatide) prescribing information, FDA. DailyMed
Read the guide →
What to eat on a GLP‑17 sources
  • Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. American Journal of Clinical Nutrition, 2025;122:344–367 (also published in Obesity). doi.org/10.1016/j.ajcnut.2025.04.023
  • The Obesity Society. Nutritional priorities to support GLP-1 therapy for obesity. obesity.org
  • US Departments of Agriculture and Health and Human Services. Dietary Guidelines for Americans, 2025–2030. cdn.realfood.gov/DGA.pdf
  • American Academy of Family Physicians. Dietary Guidelines for 2025–2030: recommendations from the USDA and HHS. American Family Physician, 2026. aafp.org
  • National Academies. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. 2005. nap.nationalacademies.org
  • Wegovy (semaglutide) prescribing information, FDA. DailyMed
  • Zepbound (tirzepatide) prescribing information, FDA. DailyMed
Read the guide →
A 7-day GLP‑1 meal plan7 sources
  • Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. American Journal of Clinical Nutrition, 2025;122:344–367. doi.org/10.1016/j.ajcnut.2025.04.023
  • Full text of the joint advisory, American Journal of Lifestyle Medicine, 2025. pmc.ncbi.nlm.nih.gov/articles/PMC12125019
  • US Department of Agriculture, Agricultural Research Service. FoodData Central (SR Legacy). fdc.nal.usda.gov
  • US Department of Agriculture. Leftovers and food safety. usda.gov
  • US Departments of Agriculture and Health and Human Services. Dietary Guidelines for Americans, 2025–2030. cdn.realfood.gov/DGA.pdf
  • Wegovy (semaglutide) prescribing information, FDA. DailyMed
  • Zepbound (tirzepatide) prescribing information, FDA. DailyMed
Read the guide →
Food noise and GLP‑1 medicines10 sources
  • Hayashi D, et al. What is food noise? A conceptual model of food cue reactivity. Nutrients, 2023;15(22):4809. doi.org/10.3390/nu15224809
  • Dhurandhar EJ, et al. Food noise: definition, measurement, and future research directions. Nutrition & Diabetes, 2025;15:30. doi.org/10.1038/s41387-025-00382-x
  • Diktas HE, et al. Development and validation of the Food Noise Questionnaire. Obesity, 2025;33(2):289–297. doi.org/10.1002/oby.24216
  • Friedrichsen M, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism, 2021;23:754–762. doi.org/10.1111/dom.14280
  • Penn Medicine. Tirzepatide may only temporarily suppress brain activity involved in "food noise" (news release on a Nature Medicine case report), November 2025. newswise.com
  • Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022;24(8):1553–1564. doi.org/10.1111/dom.14725
  • Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA, 2024;331(1):38–48. jamanetwork.com
  • Nedeltcheva AV, et al. Insufficient sleep undermines dietary efforts to reduce adiposity. Annals of Internal Medicine, 2010. pubmed.ncbi.nlm.nih.gov/20921542
  • Wegovy (semaglutide) prescribing information, FDA. DailyMed
  • Zepbound (tirzepatide) prescribing information, FDA. DailyMed
Read the guide →
Alcohol on a GLP‑1: what to know before you drink10 sources
  • Wegovy (semaglutide) injection and tablets, prescribing information and Medication Guide. Novo Nordisk. DailyMed
  • Ozempic (semaglutide) injection, prescribing information and Medication Guide. Novo Nordisk. DailyMed
  • Zepbound (tirzepatide) injection, prescribing information and Medication Guide. Eli Lilly. DailyMed
  • Mounjaro (tirzepatide) injection, prescribing information and Medication Guide. Eli Lilly. DailyMed
  • Hendershot CS et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2025;82(4):395-405. PubMed
  • American Diabetes Association. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2025. Diabetes Care 2025;48(Suppl 1). Diabetes Care
  • National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms and Causes of Pancreatitis. NIDDK
  • National Institute on Alcohol Abuse and Alcoholism. What Is A Standard Drink? NIAAA
  • National Institute on Alcohol Abuse and Alcoholism. Hangovers. NIAAA
  • 2020 Dietary Guidelines Advisory Committee. Scientific Report, Part D, Chapter 11: Alcoholic Beverages. DietaryGuidelines.gov
Read the guide →
Muscle loss on a GLP‑1, and how to protect it7 sources
  • Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 2025;27(5):2720–2729. doi.org/10.1111/dom.16275
  • Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021;384:989–1002. doi.org/10.1056/NEJMoa2032183
  • Wilding JPH, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. Journal of the Endocrine Society, 2021 (ENDO 2021 abstract). newswise.com
  • Tinsley GM, et al. Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: a case series. SAGE Open Medical Case Reports, 2025;13. Summarizes the STEP 1 DXA figures. doi.org/10.1177/2050313X251388724
  • Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory. American Journal of Clinical Nutrition, 2025;122:344–367. doi.org/10.1016/j.ajcnut.2025.04.023
  • US Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd edition. odphp.health.gov
  • US Departments of Agriculture and Health and Human Services. Dietary Guidelines for Americans, 2025–2030. cdn.realfood.gov/DGA.pdf
Read the guide →
Exercise on a GLP‑1: where to start10 sources
  • US Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd edition, 2018. Executive summary. odphp.health.gov
  • Office of Disease Prevention and Health Promotion. Top 10 things to know about the second edition of the Physical Activity Guidelines for Americans. odphp.health.gov
  • Centers for Disease Control and Prevention. Measuring physical activity intensity. cdc.gov
  • Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. American Journal of Clinical Nutrition, 2025;122:344–367. doi.org/10.1016/j.ajcnut.2025.04.023
  • Full text of the joint advisory, American Journal of Lifestyle Medicine, 2025. pmc.ncbi.nlm.nih.gov/articles/PMC12125019
  • Lundgren JR, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. New England Journal of Medicine, 2021;384:1719–1730. pubmed.ncbi.nlm.nih.gov/33951361
  • Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 2025;27(5):2720–2729. doi.org/10.1111/dom.16275
  • Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021;384:989–1002. doi.org/10.1056/NEJMoa2032183
  • Zepbound (tirzepatide) prescribing information, FDA. DailyMed
  • Wegovy (semaglutide) prescribing information, FDA. DailyMed
Read the guide →
GLP‑1s in perimenopause and menopause10 sources
  • Tchang BG, et al. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity, 2025;33:851–860. doi.org/10.1002/oby.24254
  • Greendale GA, et al. Changes in body composition and weight during the menopause transition. JCI Insight, 2019;4(5):e124865. doi.org/10.1172/jci.insight.124865
  • Hurtado MD, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause, 2024;31(4):266–274. doi.org/10.1097/GME.0000000000002310
  • Castaneda R, et al. The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study. The Lancet Obstetrics, Gynaecology & Women's Health, 2026;2(2):e118–e128. doi.org/10.1016/S3050-5038(25)00145-100145-1)
  • The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022;29(7):767–794. menopause.org
  • Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory. American Journal of Clinical Nutrition, 2025;122:344–367. doi.org/10.1016/j.ajcnut.2025.04.023
  • Zepbound (tirzepatide) prescribing information, Eli Lilly and Company. DailyMed
  • Wegovy (semaglutide) prescribing information, Novo Nordisk. DailyMed
  • US Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd edition. odphp.health.gov
  • US Departments of Agriculture and Health and Human Services. Dietary Guidelines for Americans, 2025–2030. cdn.realfood.gov/DGA.pdf
Read the guide →
GLP‑1s and PCOS: what the research shows9 sources
  • Teede HJ, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology & Metabolism, 2023;108(10):2447–2469. doi.org/10.1210/clinem/dgad463
  • Austregésilo de Athayde De Hollanda Morais B, et al. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: a meta-analysis of randomized controlled trials. Journal of Diabetes and its Complications, 2024;38:108834. doi.org/10.1016/j.jdiacomp.2024.108834
  • Goldberg A, et al. Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obesity Reviews, 2024;25:e13704. doi.org/10.1111/obr.13704
  • Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reproductive BioMedicine Online, 2019;39:332–342. doi.org/10.1016/j.rbmo.2019.04.017
  • Wegovy (semaglutide) prescribing information, Novo Nordisk. DailyMed
  • Ozempic (semaglutide) prescribing information, Novo Nordisk. DailyMed
  • Zepbound (tirzepatide) prescribing information, Eli Lilly and Company. DailyMed
  • Mounjaro (tirzepatide) prescribing information, Eli Lilly and Company. DailyMed
  • US Departments of Agriculture and Health and Human Services. Dietary Guidelines for Americans, 2025–2030. cdn.realfood.gov/DGA.pdf
Read the guide →
Wegovy tracker: an app for your Wegovy journey3 sourcesRead the guide →
Ozempic tracker: an app for your Ozempic journey2 sourcesRead the guide →
Zepbound tracker: an app for your Zepbound journey3 sourcesRead the guide →
Mounjaro tracker: an app for your Mounjaro journey3 sourcesRead the guide →
The best GLP‑1 tracker apps, compared fairly10 sourcesRead the guide →
Ready when you are

Start your morning, today.

Seven days of everything, free. No free tier that hides the useful parts.

Download for iOS

7 days free · Nothing charged today